Protective effect and mechanism of astragaloside IV on oxidative stress injury of mesangial cells

Zhongguo Zhongyao Zazhi

Volumn 38, Issue 5, 2013, Pages 725-730

  Cao, Ling Ling ^a,b   Li, Wei Zu ^a   Si, Xiu Lian ^a   Sun, Li ^a   Li, Wei Ping ^a,c  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Huainan Union University   (China)

^c Anqing Medical and Pharmaceutical College   (China)

Author keywords

Astragaloside IV; Cyclin D1; Hydrogen peroxide; Mesangial cell; Oxidative stress; ROS

Indexed keywords

ASTRAGALOSIDE IV; CYCLIN A; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DAMAGE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MESANGIUM CELL; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CELL LINE; CELL SURVIVAL; CYCLIN A; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; HYDROGEN PEROXIDE; MESANGIAL CELLS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SAPONINS; TRITERPENES;

EID: 84877067338     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20130522     Document Type: Article

References (18)

1. 2011, 36(24): 3494.
2. Vaugham M R, Quaggin S E. How do mesangial and endothelial cells for the glomerular tuft[J]. Jam Soc Nehprol, 2008, 19(1): 24.
3. 2010, 35(4): 525.
4. Huang Y, Border W A, Noble N A. Functional renin receptors in ren mesangial cells[J]. Curr Hypertens Rep, 2007, 9(2): 133.
5. 2008, 6(5): 518.
6. 2007, 42(4): 381.
7. Lei Hong, Wang Bing, Li Weiping, et al. Anti-aging effect of astragalosides and its mechanism of action[J]. Acta Pharmacol Sin, 2003, 24(3): 230.
8. 2009, 5(10): 1330.
9. 2009, 34(2): 199.
10. Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic diabetic kidney disease[J]. Mayo Clinproc, 2008, 83(12): 1373.
11. Cortinovis M, Cattaneo D, Perico N, et al. Investigationaldrugs for diabeticnephropat[J]. Expert Opin Investig Drugs, 2008, 17(10): 1487.
12. Gartner V, Eigentler T K. Pathogenesis of diabetic macro-and microangio-pathy[J]. Clin Nephrol, 2008, 70(1): 1.
13. Stambe C, Atkins R C. The role of p38 alpha mitogen-activated protein kinase activation in renal fibrosis[J]. J Am Soc Nephrol, 2004, 15(2): 370.
14. Stacey D W. Cyclin D1 selves as a cell cycle regulatory switch iactively proliferating cells[J]. Curr Opin Cell Biol, 2003, 15(2): 158.
15. Simile M M, Miglio M R, Muroni M R, et al. Down-regulation of c-myc and Cyclin Dl genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 ang Morris 5123 liver cancer cells[J]. Carcinogenesis, 2004, 25(3): 333.
16. Sakai N, Wada T. p38 Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy[J]. Am J Kidney Dis, 2005, 45(1): 54.
17. Darren J Fernandes, Claire E Ravenhall, Trudi Harris, et al. Contribution of the p38MAPK signalling pathway to proliferation in human cultured airway smooth muscle cells is mitogen-specific[J]. Bri J Pharm, 2004, 142: 1182.
18. Felix B Engel, Michael Schebesta, Mychelle T Duong, et al. P38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes[J]. Genes Dev, 2005, 19: 1175.